VANCOUVER, British Columbia, Feb. 6, 2018 /CNW/ -- LightIntegra Technology Inc., creators of ThromboLUX, the first analyzer to provide a routine test for platelet activation status, announced today that Jim LaFrance has been appointed to its Board of Directors.
Jim LaFrance brings 30 years of experience in US diagnostic device commercialization to LightIntegra. Mr. LaFrance has extensive experience in various commercialization roles including Board Director, CEO, commercial general management, sales management, and strategic marketing.
"Jim's addition to the Board is ideal, as we have just started commercializing the ThromboLUX System in the US market," said Bill Dubiel, President and CEO of LightIntegra Technology. "His US commercial knowledge and experience building customer, company, and shareholder value is an important attribute to the Board."
Mr. LaFrance currently serves as the Chairman of the Board at Vermillion Inc., Executive Chairman of Bioarray Genetics, and is on the Board of Directors for both HTG Molecular Inc. and Personal Genome Diagnostics.
"It is great to have Jim join our strong Board of Directors," said Paul Geyer, Chairman of the Board for LightIntegra. "His experience and advice regarding commercialization of diagnostic devices and strategic transactions will be a welcome addition to the LightIntegra Board."
As a member of the LightIntegra Board, Mr. LaFrance will be able to pull on his wealth of experience in commercial leadership roles at this exciting time for the company. His experience includes being the Interim CEO at Vermillion Inc. from April 2014 to December 2014, CEO of Omnyx LLC within GE Healthcare from January 2012 to October 2013, CEO and President for LaFrance Consulting LLC from August 2009 to December 2011 and Head of International Commercial Operations at Ventana which culminated in the $3.4 billion acquisition of Ventana by Roche in 2008.
"I am pleased to be joining the LightIntegra Board of Directors and look forward to working with management in their efforts to further the important work in improving transfusion medicine safety and quality," stated Mr. LaFrance.
About LightIntegra Technology Inc.
LightIntegra Technology exists because of failed platelet transfusions. Failed platelet transfusions are a major issue in healthcare, critically impacting the care of blood cancer patients, and wasting $1.6 billion annually in the US. LightIntegra knows how painful failed transfusions are for physicians, the blood bank, and most importantly, the patients. Understanding this struggle is what gave birth to ThromboLUX, the first analyzer to provide a routine test for platelet activation status. LightIntegra strives to give patients the best possible chance for platelet transfusion success by ensuring all hematology-oncology patients receive non-activated platelets.
SOURCE LightIntegra Technology, Inc.